Titan Pharmaceuticals (NASDAQ:TTNP) Earns Sell Rating from Analysts at StockNews.com

Equities research analysts at StockNews.com initiated coverage on shares of Titan Pharmaceuticals (NASDAQ:TTNP) in a report released on Monday. The firm set a “sell” rating on the specialty pharmaceutical company’s stock.

Titan Pharmaceuticals Stock Performance

TTNP stock opened at $4.02 on Monday. Titan Pharmaceuticals has a twelve month low of $3.51 and a twelve month high of $14.80. The business has a 50 day moving average price of $4.58 and a two-hundred day moving average price of $5.57.

Titan Pharmaceuticals Company Profile

Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.